Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 15, 2023

BUY
$1.25 - $4.05 $44,250 - $143,370
35,400 Added 354.0%
45,400 $57,000
Q4 2022

Feb 14, 2023

BUY
$0.67 - $3.03 $6,700 - $30,299
10,000 New
10,000 $30,000

Others Institutions Holding GLYC

About GLYCOMIMETICS INC


  • Ticker GLYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,423,900
  • Market Cap $14.7M
  • Description
  • GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...
More about GLYC
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.